RebeccaWangSilbermannMD

Oncology • Portland, OR

Hematologic Oncology

Physician

Join to view full profile

Dr. Silbermann is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Silbermann's full profile

Already have an account?

Office
3181 SW Sam Jackson Park Rd., OC14HO
Portland, OR 97239

Education & Training

UPMC Medical EducationFellowship, Hematology and Medical Oncology, 2008 - 2011
University of RochesterResidency, Internal Medicine, 2004 - 2007
The Warren Alpert Medical School of Brown UniversityClass of 2004

Certifications & Licensure

ID State Medical License 2021 - 2026
WA State Medical License 2016 - 2026
OR State Medical License 2017 - 2025
IN State Medical License 2012 - 2017
PA State Medical License 2008 - 2012
NY State Medical License 2007 - 2008
American Board of Internal Medicine Hematology

Clinical Trials

A Phase IIa Study of Sotatercept on Bone Mass and Turnover in Patients With Multiple Myeloma Start of enrollment: 2014 Oct 01
Withdrawn
Phase 2
COMbination Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomide Start of enrollment: 2023 Jan 18
Recruiting
Phase 1, Phase 2
Roles: Contact
Isatuximab, Carfilzomib, and Pomalidomide for the Treatment of Relapsed or Refractory Multiple Myeloma Start of enrollment: 2022 Jun 14
Active, not recruiting
Phase 2
Roles: Principal Investigator, Contact
A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma Start of enrollment: 2017 Oct 04
Active, not recruiting
Phase 1, Phase 2
Roles: Principal Investigator
Join now to see all

Publications & Presentations

PubMed

A plain language summary of the final analysis of the GRIFFIN study of daratumumab plus lenalidomide, bortezomib, and dexamethasone for people with newly diagnosed mul...
Peter M Voorhees, Douglas W Sborov, Jacob Laubach, Jonathan L Kaufman, Brandi Reeves
Future Oncology. 2024-10-25
5 citations
Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma.
Naresh Bumma, Joshua Richter, Sundar Jagannath, Hans C Lee, James E Hoffman
Journal of Clinical Oncology. 2024-08-01
3 citations
Daratumumab in transplant-eligible patients with newly diagnosed multiple myeloma: final analysis of clinically relevant subgroups in GRIFFIN.
Ajai Chari, Jonathan L Kaufman, Jacob Laubach, Douglas W Sborov, Brandi Reeves
Blood Cancer Journal. 2024-07-08

Abstracts/Posters

Preliminary Results from a Phase 1b Study of TAK-079, an Investigational Anti-CD38 Monoclonal Antibody (mAb) in Patients with Relapsed/ Refractory Multiple Myeloma (RRMM)
Rebecca W. Silbermann, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
High-Throughput Functional Drug Screening and Genomic Analysis to Guide Individualized Therapy for Relapsed/Refractory Multiple Myeloma
Rebecca W. Silbermann, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Depth of Response to Daratumumab (DARA), Lenalidomide, Bortezomib, and Dexamethasone (RVd) Improves over Time in Patients (pts) with Transplant-Eligible Newly Diagnose...
Rebecca W. Silbermann, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd) Induction, Autologous Transplantation and Post-Transplant, Response-Adapted, Measurable Residual Di...
Rebecca W. Silbermann, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Press Mentions

Daratumumab Regimen Confers Health-Related Quality of Life Benefit in Multiple MyelomaDecember 11th, 2022
Multiple Myeloma: Choosing Your PathDecember 18th, 2020
OncLive® Presents Seven State of the Science Summit™ Meetings in MarchFebruary 26th, 2020
Join now to see all